Drug interactions
Linagliptin-metformin + Tazemetostat
Severity: Moderate
Linagliptin-metformin and Tazemetostat: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tazemetostat is a weak-to-moderate CYP3A4 inducer and may lower linagliptin exposure. The reduction is expected to be modest but could slightly weaken glycemic control.
What this interaction means in plain words
Linagliptin-metformin and Tazemetostat can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Linagliptin-metformin belongs to Endocrine; Tazemetostat belongs to Miscellaneous.
Why it happens
CYP3A4 induction by tazemetostat increases linagliptin metabolism.
What to do
Monitor blood glucose and HbA1c, and consider adjusting antidiabetic therapy if control deteriorates.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Linagliptin-metformin and Tazemetostat, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Tazemetostat
Frequently asked questions
Can I take Linagliptin-metformin with Tazemetostat?
MediHelp rates the interaction as moderate. Linagliptin-metformin and Tazemetostat can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tazemetostat is a weak-to-moderate CYP3A4 inducer and may lower linagliptin exposure. The reduction is expected to be modest but could slightly weaken glycemic control.
How serious is the interaction between Linagliptin-metformin and Tazemetostat?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose and HbA1c, and consider adjusting antidiabetic therapy if control deteriorates.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
